3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
2
Brain Neoplasms
2
Seizures
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Glioma
1
Interventions
Rituximab
134
Cyclophosphamide
100
Vincristine
53
fludarabine phosphate
50
Prednisone
50
Doxorubicin
49
Etoposide
47
Peripheral Blood Stem Cell Transplantation
38
Mycophenolic Acid
37
Whole-Body Irradiation
35
Tacrolimus
29
Busulfan
27
Lenalidomide
26
Filgrastim
26
Cyclosporine
26
Melphalan
24
Methotrexate
21
Antilymphocyte Serum
21
Gemcitabine
18
ibritumomab tiuxetan
17
Granulocyte Colony-Stimulating Factor
17
Cytarabine
17
Carmustine
16
Radiotherapy
15
fludarabine
14
Carboplatin
14
Bendamustine Hydrochloride
14
pembrolizumab
13
ibrutinib
12
Sirolimus
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Large B-Cell, Diffuse
×
Levetiracetam
×
Clear all
NCT02348216
2024-06-04
ZUMA-1
Gilead Sciences
Phase 1/2
Completed
307 enrolled
41 charts